144 related articles for article (PubMed ID: 11084219)
1. Effect of venlafaxine on imipramine metabolism.
Albers LJ; Reist C; Vu RL; Fujimoto K; Ozdemir V; Helmeste D; Poland R; Tang SW
Psychiatry Res; 2000 Nov; 96(3):235-43. PubMed ID: 11084219
[TBL] [Abstract][Full Text] [Related]
2. Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.
Ball SE; Ahern D; Scatina J; Kao J
Br J Clin Pharmacol; 1997 Jun; 43(6):619-26. PubMed ID: 9205822
[TBL] [Abstract][Full Text] [Related]
3. A possible bupropion and imipramine interaction.
Shad MU; Preskorn SH
J Clin Psychopharmacol; 1997 Apr; 17(2):118-9. PubMed ID: 10950476
[No Abstract] [Full Text] [Related]
4. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
[TBL] [Abstract][Full Text] [Related]
5. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the pharmacokinetics of venlafaxine extended release and desvenlafaxine in extensive and poor cytochrome P450 2D6 metabolizers.
Preskorn S; Patroneva A; Silman H; Jiang Q; Isler JA; Burczynski ME; Ahmed S; Paul J; Nichols AI
J Clin Psychopharmacol; 2009 Feb; 29(1):39-43. PubMed ID: 19142106
[TBL] [Abstract][Full Text] [Related]
7. Steady-state plasma concentrations of imipramine and desipramine in relation to S-mephenytoin 4'-hydroxylation status in Japanese depressive patients.
Koyama E; Tanaka T; Chiba K; Kawakatsu S; Morinobu S; Totsuka S; Ishizaki T
J Clin Psychopharmacol; 1996 Aug; 16(4):286-93. PubMed ID: 8835703
[TBL] [Abstract][Full Text] [Related]
8. Venlafaxine serum levels and CYP2D6 genotype.
Veefkind AH; Haffmans PM; Hoencamp E
Ther Drug Monit; 2000 Apr; 22(2):202-8. PubMed ID: 10774634
[TBL] [Abstract][Full Text] [Related]
9. Effect of desvenlafaxine on the cytochrome P450 2D6 enzyme system.
Preskorn SH; Nichols AI; Paul J; Patroneva AL; Helzner EC; Guico-Pabia CJ
J Psychiatr Pract; 2008 Nov; 14(6):368-78. PubMed ID: 19057238
[TBL] [Abstract][Full Text] [Related]
10. Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.
Lindh JD; Annas A; Meurling L; Dahl ML; AL-Shurbaji A
Eur J Clin Pharmacol; 2003 Sep; 59(5-6):401-6. PubMed ID: 12898080
[TBL] [Abstract][Full Text] [Related]
11. Effects of desvenlafaxine on the pharmacokinetics of desipramine in healthy adults.
Nichols AI; Abell M; Chen Y; Behrle JA; Frick G; Paul J
Int Clin Psychopharmacol; 2013 Mar; 28(2):99-105. PubMed ID: 23221858
[TBL] [Abstract][Full Text] [Related]
12. Impact of age on serum concentrations of venlafaxine and escitalopram in different CYP2D6 and CYP2C19 genotype subgroups.
Waade RB; Hermann M; Moe HL; Molden E
Eur J Clin Pharmacol; 2014 Aug; 70(8):933-40. PubMed ID: 24858822
[TBL] [Abstract][Full Text] [Related]
13. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
[TBL] [Abstract][Full Text] [Related]
14. The Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.
Nguyen HQ; Callegari E; Obach RS
Drug Metab Dispos; 2016 Oct; 44(10):1569-78. PubMed ID: 27440861
[TBL] [Abstract][Full Text] [Related]
15. Nifedipine Does Not Alter the Pharmacokinetics of Venlafaxine Enantiomers in Healthy Subjects Phenotyped for CYP2D6, CYP2C19, and CYP3A.
Tozatto E; Benzi JRL; Rocha A; Coelho EB; Lanchote VL
J Clin Pharmacol; 2021 Mar; 61(3):319-327. PubMed ID: 32974907
[TBL] [Abstract][Full Text] [Related]
16. Effect of terbinafine on the pharmacokinetics and pharmacodynamics of desipramine in healthy volunteers identified as cytochrome P450 2D6 (CYP2D6) extensive metabolizers.
Madani S; Barilla D; Cramer J; Wang Y; Paul C
J Clin Pharmacol; 2002 Nov; 42(11):1211-8. PubMed ID: 12412819
[TBL] [Abstract][Full Text] [Related]
17. An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects.
Patroneva A; Connolly SM; Fatato P; Pedersen R; Jiang Q; Paul J; Guico-Pabia C; Isler JA; Burczynski ME; Nichols AI
Drug Metab Dispos; 2008 Dec; 36(12):2484-91. PubMed ID: 18809731
[TBL] [Abstract][Full Text] [Related]
18. The effect of sertraline on the pharmacokinetics of desipramine and imipramine.
Kurtz DL; Bergstrom RF; Goldberg MJ; Cerimele BJ
Clin Pharmacol Ther; 1997 Aug; 62(2):145-56. PubMed ID: 9284850
[TBL] [Abstract][Full Text] [Related]
19. Alternative venlafaxine kinetics in overdose.
Langford NJ; Martin U; Ruprah M; Ferner RE
J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987
[TBL] [Abstract][Full Text] [Related]
20. Effect of ketoconazole on the pharmacokinetics of imipramine and desipramine in healthy subjects.
Spina E; Avenoso A; Campo GM; Scordo MG; Caputi AP; Perucca E
Br J Clin Pharmacol; 1997 Mar; 43(3):315-8. PubMed ID: 9088587
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
